Combination treatment before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of two drugs (cadonilimab and anlotinib) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have esophageal squamous cell carcinoma that is locally advanced but still removable with surgery.
- You must not have had any prior treatment for this cancer (like chemo or radiation).
- You must have a tumor sample (biopsy) available for testing.
- Your doctor must confirm that surgery can be done with curative intent.
- You must be in generally good health with adequate organ function (heart, lungs, liver, kidneys).
- You must not have an active autoimmune disease or another cancer in the last 2 years.
- You must not have uncontrolled diabetes or high blood pressure.
- You must be willing to use effective contraception if applicable.
- You must not have had major surgery within the last 28 days.
- You must not have a history of stroke, heart attack, or severe heart failure in the last 6 months.
- You must not have a severe infection or certain viral infections (like untreated HIV, hepatitis B, or hepatitis C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests a combination of two drugs (cadonilimab and anlotinib) followed by radiation therapy for esophageal cancer that has returned or spread. The goal is to see if this approach helps shrink tumors and control the disease.
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
Hear when a new Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.